Gemifioxacin mesylate CAS NO.210353-53-0

We specialized in APIS/ Intermediates and Focus on Technical more than 10 years.we have a perfect research and development technology and manufacturing. We have more advantages of technical and price.

      Gemifloxacin is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, orMoraxella catarrhalis. Community-acquired pneumonia (of mild to moderate severity) caused by S. pneumoniae (including multi-drug resistant strains, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae.

Gemifloxacin has been shown to be active against most strains of the following microorganisms   

including multi-drug resistant Streptococcus pneumoniae (MDRSP). MDRSP includes isolates previously known as PRSP (penicillin-resistantStreptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g.,cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.